{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:36:51Z","timestamp":1771735011295,"version":"3.50.1"},"reference-count":15,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["205829"],"award-info":[{"award-number":["205829"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-retroviral therapy (ART) simplification strategies are needed for treatment-experienced people with HIV (PWH) and multidrug-resistant viruses. These individuals are commonly treated with boosted ART regimens and are thereby at risk for harmful drug-drug interactions (DDI). In this trial, we aim to assess the efficacy of the combination doravirine, dolutegravir and lamivudine (DOR\/DTG\/3TC) among people with a history of virological failure who receive boosted ART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>B-Free is a multistage, randomised, multicentre, open-label, non-inferiority trial, embedded within the Swiss HIV Cohort Study and conducted in collaboration with cohorts of PWH in the Netherlands and France. Cohort participants with a history of ART change due to virologic failure and who maintain HIV virologic suppression with an ART regimen consisting of a pharmacological booster and at least two drugs from classes other than nucleoside reverse transcriptase inhibitors are included. Patients with major drug resistance mutations against DTG or DOR and individuals with chronic hepatitis B virus infection are not eligible for the study. Individuals are randomised 1:1 to either receiving co-formulated DTG\/3TC and DOR once daily or continuing their boosted ART regimen. The primary outcome is the proportion of individuals lacking virologic control (HIV-RNA \u226550\u2009cp\/mL) at 48 weeks, according to the Food and Drug Administration snapshot algorithm. Changes in DDI burden (assessed using a DDI score), treatment satisfaction (assessed using the HIV Treatment Satisfaction Questionnaire), quality of life and mental health represent key secondary outcomes. Additional secondary outcomes include the proportion of individuals developing new resistance-associated mutations and changes in quality of life and mental health. In a qualitative substudy, we will conduct semistructured interviews with a subset of participants to assess their expectations and experiences towards HIV treatment and clinical research in general. Enrolling 210 individuals will provide 80% power to demonstrate non-inferiority, defined as less than 8% absolute increase in loss of viral suppression in individuals randomised to DOR\/DTG\/3TC (one-sided type I error rate of 0.025).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study was approved by the competent ethics committees (reference number BASEC 2023\u201301060) and the regulatory authority Swissmedic (reference number 701655) in Switzerland before the enrolment of the first participant. Approval by the European Medicines Agency and local ethical committees in the Netherlands and France will be obtained prior to including participants in these countries. Participant\u2019s written informed consent is obtained by the investigators before enrolment. The results of all major B-Free study outcomes will be submitted to peer-reviewed journals that enable Open Access publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      Swiss National Clinical Trials Portal (SNCTP000005686, registered on 06 November 2023) and Clinicaltrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06037564\">NCT06037564<\/jats:ext-link>\n                      , registered on 07 September 2023).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-094912","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:48:18Z","timestamp":1732243698000},"page":"e094912","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free): protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct06037564","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marie","family":"Ballif","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[{"name":"HIV Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enos","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Lausanne, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Tissot","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital of Lausanne, University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Stoeckle","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Schmid","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital of St Gallen, St Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph A","family":"Fux","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cantonal Hospital of Aarau, Aarau, Switzerland, Aarau, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Van der Valk","sequence":"additional","affiliation":[{"name":"HIV Monitoring Foundation, Amsterdam, Netherlands"},{"name":"Amsterdam UMC, University of Amsterdam, Department of Infectious Diseases and Amsterdam Institute for Immunology & Infectious diseases, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kees","family":"Brinkman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, OLVG, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Mudrikova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, 3584 CX, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Institut Bergoni\u00e9, BPH, Bordeaux, France"},{"name":"CHU Bordeaux, H\u00f4pital Saint-Andr\u00e9, Service de M\u00e9decine Interne et Maladies Infectieuses, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Leleux","sequence":"additional","affiliation":[{"name":"University of Bordeaux, INSERM, Institut Bergoni\u00e9, BPH, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Sa\u00fade","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Hirter","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Schwab","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"HIV Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Limacher","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Rintelen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Kouyos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland"},{"name":"Institute of Medical Virology, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Haerry","sequence":"additional","affiliation":[{"name":"Chair Positive Council, Z\u00fcrich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia C.","family":"Zambrano","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Egloff","sequence":"additional","affiliation":[{"name":"Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Akre","sequence":"additional","affiliation":[{"name":"Centre for Primary Care and Public Health (Unisant\u00e9), University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-8781","authenticated-orcid":false,"given":"Isabelle","family":"Peytremann-Bridevaux","sequence":"additional","affiliation":[{"name":"Centre for Primary Care and Public Health (Unisant\u00e9), University of Lausanne, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andri","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Wandeler","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-974X","authenticated-orcid":false,"given":"Bernard","family":"Surial","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"2025121219483666000_14.11.e094912.1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2025121219483666000_14.11.e094912.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"2025121219483666000_14.11.e094912.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"2025121219483666000_14.11.e094912.4","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001193"},{"key":"2025121219483666000_14.11.e094912.5","doi-asserted-by":"crossref","first-page":"e2145","DOI":"10.1093\/cid\/ciaa918","article-title":"Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors","volume":"73","author":"Deutschmann","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025121219483666000_14.11.e094912.6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02016-18","article-title":"Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions","volume":"63","author":"Khalilieh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121219483666000_14.11.e094912.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02650-15"},{"key":"2025121219483666000_14.11.e094912.8","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyab141"},{"key":"2025121219483666000_14.11.e094912.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022516","article-title":"AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile","volume":"8","author":"Boender","year":"2018","journal-title":"BMJ Open"},{"key":"2025121219483666000_14.11.e094912.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152970","article-title":"Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000-2012","volume":"11","author":"Collin","year":"2016","journal-title":"PLoS One"},{"key":"2025121219483666000_14.11.e094912.11","first-page":"376","article-title":"Adaptive trial designs: what are multiarm, multistage trials?","volume":"105","author":"Millen","year":"2020","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2025121219483666000_14.11.e094912.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"2025121219483666000_14.11.e094912.13","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER) . Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment."},{"key":"2025121219483666000_14.11.e094912.14","unstructured":"The University of Liverpool . HIV drug interactions. Available: https:\/\/www.hiv-druginteractions.org\/ [Accessed 29 Jan 2024]."},{"key":"2025121219483666000_14.11.e094912.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003421","article-title":"Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL\u2019HIV trial","volume":"17","author":"Sculier","year":"2020","journal-title":"PLoS Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-094912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:48:46Z","timestamp":1765597726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-094912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,21]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bmjopen-2024-094912"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-094912","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}